Study to Evaluate Safety and Efficacy in Adult Subjects With ITP

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 17, 2014

Primary Completion Date

January 22, 2018

Study Completion Date

January 22, 2018

Conditions
Immune Thrombocytopenic Purpura
Interventions
DRUG

BMS-986004 75 mg IV

BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes

DRUG

BMS-986004 225 mg IV

BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes

DRUG

BMS-986004 675 mg IV

BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes

DRUG

BMS-986004 1500 mg IV

BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes

Trial Locations (20)

2031

Local Institution, Randwick

4102

Local Institution, Brisbane

20007

Georgetown University Medical Center, Washington D.C.

30322

Emory University, Atlanta

31904

Columbus Regional Research Institute, Columbus

90033

Univ. Of Southern Calif. /Norris Comprehensive Cancer Center, Los Angeles

194356

Local Institution, Saint Petersburg

02114

Mass General Hospital, Boston

08903

Rutgers- Robert Wood Johnson Medical School, New Brunswick

L8S 4K1

Hamilton Health Sciences/Mc Master Univ Med Ctre, Hamilton

0112

Local Institution, Tbilisi

MD 2025

Local Institution, Chisinau

41-500

Oddzial Kliniczny Hematologii i Profilaktyki Chorob Nowotworowych, Chorzów

20-601

Specjalistyczny Gabinet Lekarski Prof. dr hab. Krzysztof Giannopoulos, Lublin

02-106

Local Institution, Warsaw

Unknown

Local Institution, Smolensk

NW1 2PG

Local Institution, London

M13 9WL

Local Institution, Manchester

G4 OSF

Local Institution, Glasgow

E1 1BB

Local Institution, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY